open access

Ahead of Print
Research paper
Submitted: 2021-03-30
Accepted: 2021-06-13
Published online: 2021-10-21
Get Citation

Fibrinogen-to-albumin ratio predicts mortality in COVID-19 patients admitted to the intensive care unit

Abdulmecit Afşin1, Hakan Tibilli2, Yusuf Hoşoğlu3, Ramazan Asoğlu3, Ahmet Süsenbük2, Sezer Markirt2, Verda Dinar Tuna4
DOI: 10.5603/ARM.a2021.0098
Affiliations
  1. Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman, Turkey
  2. Department of Cardiology, Adiyaman University Faculty of Medicine, Adiyaman, Turkey
  3. Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman, Turkey.
  4. Department of Intensive Care Unit, Adiyaman Training and Research Hospital, Adiyaman, Turkey

open access

Ahead of Print
ORIGINAL PAPERS
Submitted: 2021-03-30
Accepted: 2021-06-13
Published online: 2021-10-21

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) is an inflammatory disease, and serum albumin and fibrinogen are two important factors in systemic inflammation. We aimed to investigate the relationship between the fibrinogen-to-albumin ratio (FAR) and in-hospital mortality in COVID-19 patients admitted to the intensive care unit (ICU).
Material and methods: Patients diagnosed with COVID-19 admitted to the Adiyaman Training and Research Hospital from August to November 2020 were enrolled in this retrospective cohort study. They were divided into 2 groups based on in-hospital mortality: a survivor group (n = 188) and a non-survivor group (n = 198). FAR was calculated by dividing the fibrinogen value by the albumin value. Mortality outcomes were followed up until December 15, 2020.
Results: The average age of the patients was 71.2 ± 12.9 years, and 54% were male. On multivariate logistic analysis, diabetes mellitus (OR: 1.806; 95% CI: 1.142–2.856; p = 0.011), troponin I levels (OR: 1.776; 95% CI: 1.031–3.061; p = 0.038), and FAR (OR: 1.004; 95% CI: 1.004–1.007; p = 0.010) at ICU admission were independent predictors of in-hospital mortality in patients with COVID-19.
Conclusions: The FAR at admission was associated with mortality in patients infected with SARS-CoV-2 in the ICU.

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) is an inflammatory disease, and serum albumin and fibrinogen are two important factors in systemic inflammation. We aimed to investigate the relationship between the fibrinogen-to-albumin ratio (FAR) and in-hospital mortality in COVID-19 patients admitted to the intensive care unit (ICU).
Material and methods: Patients diagnosed with COVID-19 admitted to the Adiyaman Training and Research Hospital from August to November 2020 were enrolled in this retrospective cohort study. They were divided into 2 groups based on in-hospital mortality: a survivor group (n = 188) and a non-survivor group (n = 198). FAR was calculated by dividing the fibrinogen value by the albumin value. Mortality outcomes were followed up until December 15, 2020.
Results: The average age of the patients was 71.2 ± 12.9 years, and 54% were male. On multivariate logistic analysis, diabetes mellitus (OR: 1.806; 95% CI: 1.142–2.856; p = 0.011), troponin I levels (OR: 1.776; 95% CI: 1.031–3.061; p = 0.038), and FAR (OR: 1.004; 95% CI: 1.004–1.007; p = 0.010) at ICU admission were independent predictors of in-hospital mortality in patients with COVID-19.
Conclusions: The FAR at admission was associated with mortality in patients infected with SARS-CoV-2 in the ICU.

Get Citation

Keywords

coronavirus disease 2019, intensive care unit, fibrinogen-to-albumin ratio, mortality

About this article
Title

Fibrinogen-to-albumin ratio predicts mortality in COVID-19 patients admitted to the intensive care unit

Journal

Advances in Respiratory Medicine

Issue

Ahead of Print

Article type

Research paper

Published online

2021-10-21

DOI

10.5603/ARM.a2021.0098

Keywords

coronavirus disease 2019
intensive care unit
fibrinogen-to-albumin ratio
mortality

Authors

Abdulmecit Afşin
Hakan Tibilli
Yusuf Hoşoğlu
Ramazan Asoğlu
Ahmet Süsenbük
Sezer Markirt
Verda Dinar Tuna

References (30)
  1. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020; 55(5): 2000524.
  2. Spiezia L, Boscolo A, Poletto F, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020; 120(6): 998–1000.
  3. Lu P, Liu J, Liu N, et al. Pro-inflammatory effect of fibrinogen and FDP on vascular smooth muscle cells by IL-6, TNF-α and iNOS. Life Sci. 2011; 88(19–20): 839–845.
  4. Akirov A, Masri-Iraqi H, Atamna A, et al. Low albumin levels are associated with mortality risk in hospitalized patients. Am J Med. 2017; 130(12): 1465.e11–1465.e19.
  5. Chien SC, Chen CY, Leu HB, et al. Association of low serum albumin concentration and adverse cardiovascular events in stable coronary heart disease. Int J Cardiol. 2017; 241: 1–5.
  6. Yi S, Chen M. Decreased albumin is associated with elevated N-terminal pro-brain natriuretic peptide and poor long-term prognosis in patients with chronic heart failure. Medicine (Baltimore). 2020; 99(51): e23872.
  7. Li M, Tang C, Luo E, et al. Relation of fibrinogen-to-albumin ratio to severity of coronary artery disease and long-term prognosis in patients with non-ST elevation acute coronary syndrome. Biomed Res Int. 2020; 2020: 1860268.
  8. Zhang Yi, Xiao G. Prognostic significance of the ratio of fibrinogen and albumin in human malignancies: a meta-analysis. Cancer Manag Res. 2019; 11: 3381–3393.
  9. Bi X, Su Z, Yan H, et al. Prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count. Platelets. 2020; 31(5): 674–679.
  10. Armstrong RA, Kane AD, Kursumovic E, et al. Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. Anaesthesia. 2021; 76(4): 537–548.
  11. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020; 323(13): 1239–1242.
  12. T.C. Sağlık Bakanlığı Bilimsel Danışma Kurulu Çalışması COVID-19 (SARS-CoV-2 ENFEKSİYONU) AĞIR PNÖMONİ, ARDS, SEPSİS VE SEPTİK ŞOK YÖNETİMİ 1 Haziran 2020, Ankara. https:// covid19bilgi.saglik.gov.tr/depo/rehberler/covid19rehberi/COVID19_REHBERI_AGIR_PNOMONI_ARDS_SEPSIS_VE_SEPTIK_SOK_YONTEMI.pdf (29.03.2021).
  13. Tousoulis D, Papageorgiou N, Androulakis E, et al. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev. 2011; 25(6): 239–245.
  14. Canseco-Avila LM, Lopez-Roblero A, Serrano-Guzman E, et al. Polymorphisms -455G/A and -148C/T and fibrinogen plasmatic level as risk markers of coronary disease and major adverse cardiovascular events. Dis Markers. 2019; 2019: 5769514.
  15. Kunutsor SK, Kurl S, Zaccardi F, et al. Baseline and long-term fibrinogen levels and risk of sudden cardiac death: A new prospective study and meta-analysis. Atherosclerosis. 2016; 245: 171–180.
  16. Perico L, Benigni A, Casiraghi F, et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021; 17(1): 46–64.
  17. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4): 844–847.
  18. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18(5): 1094–1099.
  19. Lodigiani C, Iapichino G, Carenzo L, et al. Humanitas COVID-19 task force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020; 191: 9–14.
  20. Spiezia L, Boscolo A, Poletto F, et al. COVID-19-Related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020; 120(6): 998–1000.
  21. Godoy L, Goligher E, Lawler P, et al. Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19. CMAJ. 2020; 192(40): E1156–E1161.
  22. Di Micco P, Russo V, Carannante N, et al. Clotting factors in COVID-19: epidemiological association and prognostic values in different clinical presentations in an Italian cohort. J Clin Med. 2020; 9(5): 1371.
  23. Basili S, Carnevale R, Nocella C, et al. PRO‐LIVER Collaborators. Serum albumin is inversely associated with portal vein thrombosis in cirrhosis. Hepatol Commun. 2019; 3(4): 504–512.
  24. Galanakis DK. Anticoagulant albumin fragments that bind to fibrinogen/fibrin: possible implications. Semin Thromb Hemost. 1992; 18(1): 44–52.
  25. Joles JA, Willekes-Koolschijn N, Koomans HA. Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine. Kidney Int. 1997; 52(3): 761–770.
  26. Aziz M, Fatima R, Lee-Smith W, et al. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care. 2020; 24(1): 255.
  27. Violi F, Cangemi R, Romiti GF, et al. Is albumin predictor of mortality in COVID-19? Antioxid Redox Signal. 2021; 35(2): 139–142.
  28. Huang J, Cheng A, Kumar R, et al. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J Med Virol. 2020; 92(10): 2152–2158.
  29. Violi F, Ceccarelli G, Cangemi R, et al. Hypoalbuminemia, coagulopathy, and vascular disease in COVID-19. Circ Res. 2020; 127(3): 400–401.
  30. Bi X, Su Z, Yan H, et al. Prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count. Platelets. 2020; 31(5): 674–679.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl